Collegium Pharmaceutical Inc. (NASDAQ:COLL) has been given a consensus recommendation of “Buy” by the seven analysts that are covering the company. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. The average twelve-month target price among brokerages that have issued ratings on the stock in the last year is $27.60.
Several equities research analysts have recently weighed in on COLL shares. Jefferies Group reissued a “buy” rating on shares of Collegium Pharmaceutical in a research note on Thursday, September 22nd. Needham & Company LLC reissued a “buy” rating and issued a $30.00 target price on shares of Collegium Pharmaceutical in a research note on Wednesday, September 14th. Gabelli started coverage on shares of Collegium Pharmaceutical in a research note on Tuesday, September 13th. They issued a “buy” rating and a $25.00 target price on the stock. Piper Jaffray Cos. set a $23.00 target price on shares of Collegium Pharmaceutical and gave the company a “buy” rating in a research note on Thursday, August 11th. Finally, Zacks Investment Research raised shares of Collegium Pharmaceutical from a “sell” rating to a “hold” rating in a research note on Wednesday, October 12th.
Collegium Pharmaceutical (NASDAQ:COLL) traded up 2.378% during midday trading on Tuesday, reaching $17.865. 126,622 shares of the company traded hands. Collegium Pharmaceutical has a one year low of $8.24 and a one year high of $30.58. The stock’s market capitalization is $420.33 million. The company has a 50 day moving average price of $13.94 and a 200-day moving average price of $14.53.
Collegium Pharmaceutical (NASDAQ:COLL) last released its quarterly earnings data on Wednesday, August 10th. The specialty pharmaceutical company reported ($1.05) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.76) by $0.29. Analysts forecast that Collegium Pharmaceutical will post ($3.86) EPS for the current fiscal year.
In related news, Director John A. Fallon purchased 2,375 shares of Collegium Pharmaceutical stock in a transaction that occurred on Friday, August 12th. The shares were bought at an average price of $10.59 per share, with a total value of $25,151.25. Following the purchase, the director now directly owns 2,375 shares of the company’s stock, valued at approximately $25,151.25. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 37.93% of the stock is currently owned by corporate insiders.
Hedge funds and other institutional investors have recently bought and sold shares of the company. Franklin Resources Inc. increased its position in Collegium Pharmaceutical by 155.8% in the first quarter. Franklin Resources Inc. now owns 829,599 shares of the specialty pharmaceutical company’s stock worth $15,057,000 after buying an additional 505,299 shares during the period. M&T Bank Corp acquired a new position in Collegium Pharmaceutical during the first quarter worth approximately $287,000. State Street Corp increased its position in Collegium Pharmaceutical by 45.7% in the first quarter. State Street Corp now owns 110,573 shares of the specialty pharmaceutical company’s stock worth $2,009,000 after buying an additional 34,708 shares during the period. Nicholas Investment Partners LP acquired a new position in Collegium Pharmaceutical during the first quarter worth approximately $849,000. Finally, Goldman Sachs Group Inc. increased its position in Collegium Pharmaceutical by 47.7% in the first quarter. Goldman Sachs Group Inc. now owns 60,294 shares of the specialty pharmaceutical company’s stock worth $1,094,000 after buying an additional 19,460 shares during the period. 61.98% of the stock is currently owned by institutional investors.
About Collegium Pharmaceutical
Collegium Pharmaceutical, Inc is a specialty pharmaceutical company. The Company is developing and planning to commercialize abuse-deterrent products that include its DETERx platform technology for the treatment of chronic pain and other diseases. The Company’s lead product candidate, Xtampza ER (Xtampza) is an abuse-deterrent, extended-release, oral formulation of oxycodone, opioid medication.
Receive News & Ratings for Collegium Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.